Benzinga's Top Pre-Market Gainers
Sinovac Biotech (NASDAQ: SVA) moved up 8.31% to $4.17 in the pre-market session. Sinovac Biotech is expected to release its unaudited financial results for the fourth quarter on April 18, 2013.
Novavax (NASDAQ: NVAX) shares gained 5.06% to $2.70 in the pre-market session. Novavax shares have surged 110.66% over the past 52 weeks, while S&P 500 index has gained 15.95% in the same period.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.